Related Experiment Videos
Studies on vaccine control and immunogenicity of polysaccharides of Streptococcus pneumoniae
Insights
This study developed an immunoelectrophoretic method to quantify pneumococcal vaccine polysaccharides and assess their stability. Results show vaccine components are within acceptable ranges, with some polysaccharides degrading over time, impacting antibody response.
Area of Science:
- Vaccinology
- Analytical Chemistry
- Immunology
Background:
- Pneumococcal vaccines are crucial for preventing bacterial infections.
- Accurate quantification and stability assessment of vaccine components are essential for efficacy.
- Understanding polysaccharide stability and immunogenicity is key to vaccine development.
Purpose of the Study:
- To develop and validate an immunoelectrophoretic method for quantifying pneumococcal vaccine polysaccharides.
- To determine the stability of individual polysaccharide components in the final vaccine formulation.
- To evaluate the immunogenicity of a conjugated pneumococcal polysaccharide (type 19F) in a mouse model.
Main Methods:
- Immunoelectrophoresis was used to quantify 14 polysaccharide components in pneumococcal vaccines.
- Polysaccharide stability was assessed by heating and storage at controlled temperatures (37°C for 24 hr, 4°C for 12 months).
- Pneumococcal type 19F polysaccharide was conjugated to proteins (bovine serum albumin, human immunoglobulin, R61 cell wall protein) via reductive amination and tested in mice.
Main Results:
- Quantification revealed polysaccharide types were present at 80%-123% of listed concentrations.
- Polysaccharide concentrations remained stable over 12 months, but molecular sizes of types 6A and 19F declined.
- Mice immunized with 19F polysaccharide-protein conjugates showed a higher antibody response, particularly when exposed early in life.
Conclusions:
- The immunoelectrophoretic method is suitable for pneumococcal vaccine quality control.
- While overall concentrations are stable, gradual degradation of certain polysaccharide molecular sizes may occur.
- Conjugation of pneumococcal polysaccharides to proteins enhances immunogenicity, with early-life exposure potentially boosting antibody response.
Abstract:
An immunoelectrophoretic method was devised for quantitation of 14 polysaccharide components in the pneumococcal vaccine, and for determination of their stability in the final container. By this method the individual polysaccharide types, 1, 2, 3, 4, 6A, 8, 9N, 12F, 18C, 19F, 23F, and 25 (Danish nomenclature), were found to be present at 80%-123% of the manufacturer's listed concentrations. Pneumococcal polysaccharide types 3, 6A, 9N, and 19F, used as representative types, were heated at 37C for 24 hr and stored at 4 C. The concentrations of these polysaccharides remained constant over a 12-month period, and the molecular sizes of types 3 and 9N were stable during storage. In contrast, the molecular sizes of types 6A and 19F declined gradually during the 12-month storage period. Pneumococcal type 19F polysaccharide was conjugated to various proteins, i.e., bovine serum albumin, human immunoglobulin, and pneumococcal R61 cell wall protein, by the method of reductive amination. Immunization of mice with 19F polysaccharide-protein conjugates resulted in formation of more antibody than was found in the control group. Young mice exposed to pneumococcal type 19F polysaccharide-protein conjugate during gestation and suckling exhibited a greater antibody response than did mice that received no type 19F polysaccharide-protein conjugate while suckling or received the conjugate only when they were only two weeks of old.